Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Sold by Thompson Siegel & Walmsley LLC

Thompson Siegel & Walmsley LLC decreased its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 15.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 258,153 shares of the medical research company’s stock after selling 48,640 shares during the period. Bio-Rad Laboratories comprises about 1.3% of Thompson Siegel & Walmsley LLC’s portfolio, making the stock its 13th largest holding. Thompson Siegel & Walmsley LLC owned approximately 0.92% of Bio-Rad Laboratories worth $84,806,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Venturi Wealth Management LLC increased its stake in Bio-Rad Laboratories by 2,175.0% during the fourth quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 87 shares during the last quarter. Gladius Capital Management LP bought a new position in shares of Bio-Rad Laboratories during the third quarter worth about $32,000. Asset Planning Inc bought a new position in shares of Bio-Rad Laboratories during the fourth quarter worth about $33,000. UMB Bank n.a. grew its position in Bio-Rad Laboratories by 41.6% in the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock valued at $36,000 after buying an additional 32 shares in the last quarter. Finally, Cape Investment Advisory Inc. bought a new position in Bio-Rad Laboratories in the 4th quarter valued at about $38,000. Institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Stock Performance

Shares of NYSE:BIO opened at $251.53 on Thursday. The stock has a market capitalization of $7.05 billion, a P/E ratio of -3.87 and a beta of 0.99. Bio-Rad Laboratories, Inc. has a 1-year low of $244.19 and a 1-year high of $387.99. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. The business has a 50-day moving average price of $315.10 and a two-hundred day moving average price of $328.93.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. Equities analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on BIO. Royal Bank of Canada reiterated an “outperform” rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. StockNews.com lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, February 17th. Finally, Wells Fargo & Company decreased their price target on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $395.20.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.